The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

The study revealed the following findings: 36.3% of psoriasis patients had elevated high-sensitivity C-reactive protein ...

The FDA approved a supplemental new drug application for roflumilast topical foam 0.3% for the treatment of plaque psoriasis ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...

Dr. Jason Rivers, MD, FRCPC, discusses psoriasis symptoms and treatments. Hawaii's governor signs new hotel tax legislation to help cope with climate change ...

THURSDAY, May 29, 2025 (HealthDay News) — Belly flab appears to be a stronger warning sign for psoriasis than fat located ...

Learn to distinguish between nail psoriasis and nail fungus through key visual differences, associated symptoms, and ...

Clearance of ASC50 paves the way for a Phase I trial in patients with mild-to-moderate plaque psoriasis.

A new study reveals psoriasis may increase the risk of obesity and fatty liver despite skin improvements Learn why managing ...

Skin symptoms may clear with biologics in psoriasis, but hidden internal inflammation often persists, contributing to major ...